Human lectins and their roles in viral infections

Molecules

Volumn 20, Issue 2, 2015, Pages 2229-2271

  Mason, Christopher P ^a   Tarr, Alexer W ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

DC SIGN; Ficolin; Hepatitis viruses; HIV; Innate immunity; Lectin; Mannose binding lectin; Therapeutics

Indexed keywords

ANTIVIRUS AGENT; LECTIN; PROTEIN BINDING;

ANIMAL; COMPLEMENT ACTIVATION; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS INFECTION;

ANIMALS; ANTIVIRAL AGENTS; COMPLEMENT ACTIVATION; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; LECTINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; VIRUS DISEASES;

EID: 84922051376     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules20022229     Document Type: Review

References (260)

1. Loris, R. Principles of structures of animal and plant lectins. Biochim. Biophys. Acta 2002, 1572, 198-208.
2. Sekine, H.; Kenjo, A.; Azumi, K.; Ohi, G.; Takahashi, M.; Kasukawa, R.; Ichikawa, N.; Nakata, M.; Mizuochi, T.; Matsushita, M.; et al. An ancient lectin-dependent complement system in an ascidian: Novel lectin isolated from the plasma of the solitary ascidian, Halocynthia roretzi. J. Immunol. 2001, 167, 4504-4510.
3. Varki, A.; Etzler, M.E.; Cummings, R.D.; Esko, J.D. Discovery and Classification of Glycan-Binding Proteins. In Essentials of Glycobiology, 2nd ed.; Varki, A., Cummings, R.D., Esko, J.D., Freeze, H.H., Stanley, P., Bertozzi, C.R., Hart, G.W., Etzler, M.E., Eds.; Cold Spring Harbor: Laurel Hollow, NY, USA, 2009.
4. Ghazarian, H.; Idoni, B.; Oppenheimer, S.B. A glycobiology review: Carbohydrates, lectins and implications in cancer therapeutics. Acta Histochem. 2011, 113, 236-247.
5. Vigerust, D.J.; Shepherd, V.L. Virus glycosylation: Role in virulence and immune interactions. Trends Microbiol. 2007, 15, 211-218.
6. Sarma, J.V.; Ward, P.A. The complement system. Cell Tissue Res. 2011, 343, 227-235.
7. Dalziel, M.; Crispin, M.; Scanlan, C.N.; Zitzmann, N.; Dwek, R.A. Emerging principles for the therapeutic exploitation of glycosylation. Science 2014, 343, 1235681.
8. Dahl, M.R.; Thiel, S.; Matsushita, M.; Fujita, T.; Willis, A.C.; Christensen, T.; Vorup-Jensen, T.; Jensenius, J.C. MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity 2001, 15, 127-135.
9. Skjoedt, M.O.; Hummelshoj, T.; Palarasah, Y.; Honore, C.; Koch, C.; Skjodt, K.; Garred, P. A novel mannose-binding lectin/ficolin-associated protein is highly expressed in heart and skeletal muscle tissues and inhibits complement activation. J. Biol. Chem. 2010, 285, 8234-8243.
10. Stover, C.M.; Thiel, S.; Thelen, M.; Lynch, N.J.; Vorup-Jensen, T.; Jensenius, J.C.; Schwaeble, W.J. Two constituents of the initiation complex of the mannan-binding lectin activation pathway of complement are encoded by a single structural gene. J. Immunol. 1999, 162, 3481-3490.
11. Matsushita, M.; Thiel, S.; Jensenius, J.C.; Terai, I.; Fujita, T. Proteolytic activities of two types of mannose-binding lectin-associated serine protease. J. Immunol. 2000, 165, 2637-2642.
12. Dong, M.; Xu, S.; Oliveira, C.L.; Pedersen, J.S.; Thiel, S.; Besenbacher, F.; Vorup-Jensen, T. Conformational changes in mannan-binding lectin bound to ligand surfaces. J. Immunol. 2007, 178, 3016-3022.
13. Feinberg, H.; Uitdehaag, J.C.; Davies, J.M.; Wallis, R.; Drickamer, K.; Weis, W.I. Crystal structure of the CUB1-EGF-CUB2 region of mannose-binding protein associated serine protease-2. EMBO J. 2003, 22, 2348-2359.
14. Gál, P.; Harmat, V.; Kocsis, A.; Bian, T.; Barna, L.; Ambrus, G.; Vegh, B.; Balczer, J.; Sim, R.B.; Naray-Szabo, G.; et al. A true autoactivating enzyme. Structural insight into mannose-binding lectin-associated serine protease-2 activations. J. Biol. Chem. 2005, 280, 33435-33444.
15. Gingras, A.R.; Girija, U.V.; Keeble, A.H.; Panchal, R.; Mitchell, D.A.; Moody, P.C.; Wallis, R. Structural basis of mannan-binding lectin recognition by its associated serine protease MASP-1: Implications for complement activation. Structure 2011, 19, 1635-1643.
16. Ambrus, G.; Gal, P.; Kojima, M.; Szilagyi, K.; Balczer, J.; Antal, J.; Graf, L.; Laich, A.; Moffatt, B.E.; Schwaeble, W.; et al. Natural substrates and inhibitors of mannan-binding lectin-associated serine protease-1 and -2: A study on recombinant catalytic fragments. J. Immunol. 2003, 170, 1374-1382.
17. Megyeri, M.; Harmat, V.; Major, B.; Vegh, A.; Balczer, J.; Heja, D.; Szilagyi, K.; Datz, D.; Pal, G.; Zavodszky, P.; et al. Quantitative characterization of the activation steps of mannan-binding lectin (MBL)-associated serine proteases (MASPs) points to the central role of MASP-1 in the initiation of the complement lectin pathway. J. Biol. Chem. 2013, 288, 8922-8934.
18. Degn, S.E.; Jensen, L.; Olszowski, T.; Jensenius, J.C.; Thiel, S. Co-complexes of MASP-1 and MASP-2 associated with the soluble pattern-recognition molecules drive lectin pathway activation in a manner inhibitable by MAp44. J. Immunol. 2013, 191, 1334-1345.
19. Parej, K.; Hermann, A.; Donath, N.; Zavodszky, P.; Gal, P.; Dobo, J. Dissociation and re-association studies on the interaction domains of mannan-binding lectin (MBL)-associated serine proteases, MASP-1 and MASP-2, provide evidence for heterodimer formation. Mol. Immunol. 2014, 59, 1-9.
20. Wallis, R.; Shaw, J.M.; Uitdehaag, J.; Chen, C.B.; Torgersen, D.; Drickamer, K. Localization of the serine protease-binding sites in the collagen-like domain of mannose-binding protein: Indirect effects of naturally occurring mutations on protease binding and activation. J. Biol. Chem. 2004, 279, 14065-14073.
21. Iwaki, D.; Kanno, K.; Takahashi, M.; Endo, Y.; Lynch, N.J.; Schwaeble, W.J.; Matsushita, M.; Okabe, M.; Fujita, T. Small mannose-binding lectin-associated protein plays a regulatory role in the lectin complement pathway. J. Immunol. 2006, 177, 8626-8632.
22. Rosbjerg, A.; Munthe-Fog, L.; Garred, P.; Skjoedt, M.O. Heterocomplex formation between MBL/ficolin/CL-11-associated serine protease-1 and -3 and MBL/ficolin/CL-11-associated protein-1. J. Immunol. 2014, 192, 4352-4360.
23. Gulla, K.C.; Gupta, K.; Krarup, A.; Gal, P.; Schwaeble, W.J.; Sim, R.B.; O'Connor, C.D.; Hajela, K. Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology 2010, 129, 482-495.
24. Takahashi, K.; Chang, W.C.; Takahashi, M.; Pavlov, V.; Ishida, Y.; la Bonte, L.; Shi, L.; Fujita, T.; Stahl, G.L.; van Cott, E.M. Mannose-binding lectin and its associated proteases (MASPs) mediate coagulation and its deficiency is a risk factor in developing complications from infection, including disseminated intravascular coagulation. Immunobiology 2011, 216, 96-102.
25. Sirmaci, A.; Walsh, T.; Akay, H.; Spiliopoulos, M.; Sakalar, Y.B.; Hasanefendioglu-Bayrak, A.; Duman, D.; Farooq, A.; King, M.C.; Tekin, M. MASP1 mutations in patients with facial, umbilical, coccygeal, and auditory findings of Carnevale, Malpuech, OSA, and Michels syndromes. Am. J. Hum. Genet. 2010, 87, 679-686.
26. Sastry, K.; Herman, G.A.; Day, L.; Deignan, E.; Bruns, G.; Morton, C.C.; Ezekowitz, R.A. The human mannose-binding protein gene. Exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10. J. Exp. Med. 1989, 170, 1175-1189.
27. Singh, K.K.; Nathamu, S.; Adame, A.; Alire, T.U.; Dumaop, W.; Gouaux, B.; Moore, D.J.; Masliah, E.; HIV Neurobehavioral Research Center Group. Expression of mannose binding lectin in HIV-1-infected brain: Implications for HIV-related neuronal damage and neuroAIDS. Neurobehav HIV Med. 2011, 3, 41-52.
28. Jensen, P.H.; Weilguny, D.; Matthiesen, F.; McGuire, K.A.; Shi, L.; Hojrup, P. Characterization of the oligomer structure of recombinant human mannan-binding lectin. J. Biol. Chem. 2005, 280, 11043-11051.
29. Yokota, Y.; Arai, T.; Kawasaki, T. Oligomeric structures required for complement activation of serum mannan-binding proteins. J. Biochem. 1995, 117, 414-419.
30. Jensenius, H.; Klein, D.C.; van Hecke, M.; Oosterkamp, T.H.; Schmidt, T.; Jensenius, J.C. Mannan-binding lectin: Structure, oligomerization, and flexibility studied by atomic force microscopy. J. Mol. Biol. 2009, 391, 246-259.
31. Sheriff, S.; Chang, C.Y.; Ezekowitz, R.A. Human mannose-binding protein carbohydrate recognition domain trimerizes through a triple alpha-helical coiled-coil. Nat. Struct. Biol. 1994, 1, 789-794.
32. Miller, A.; Phillips, A.; Gor, J.; Wallis, R.; Perkins, S.J. Near-planar solution structures of mannose-binding lectin oligomers provide insight on activation of lectin pathway of complement. J. Biol. Chem. 2012, 287, 3930-3945.
33. Teillet, F.; Lacroix, M.; Thiel, S.; Weilguny, D.; Agger, T.; Arlaud, G.J.; Thielens, N.M. Identification of the site of human mannan-binding lectin involved in the interaction with its partner serine proteases: The essential role of Lys55. J. Immunol. 2007, 178, 5710-5716.
34. Weis, W.I.; Drickamer, K.; Hendrickson, W.A. Structure of a C-type mannose-binding protein complexed with an oligosaccharide. Nature 1992, 360, 127-134.
35. Kilpatrick, D.C. Phospholipid-binding activity of human mannan-binding lectin. Immunol. Lett. 1998, 61, 191-195.
36. Palaniyar, N.; Nadesalingam, J.; Clark, H.; Shih, M.J.; Dodds, A.W.; Reid, K.B. Nucleic acid is a novel ligand for innate, immune pattern recognition collectins surfactant proteins A and D and mannose-binding lectin. J. Biol. Chem. 2004, 279, 32728-32736.
37. Teillet, F.; Dublet, B.; Andrieu, J.P.; Gaboriaud, C.; Arlaud, G.J.; Thielens, N.M. The two major oligomeric forms of human mannan-binding lectin: Chemical characterization, carbohydrate-binding properties, and interaction with MBL-associated serine proteases. J. Immunol. 2005, 174, 2870-2877.
38. Saifuddin, M.; Hart, M.L.; Gewurz, H.; Zhang, Y.; Spear, G.T. Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1. J. Gen. Virol. 2000, 81, 949-955.
39. Wei, X.; Decker, J.M.; Wang, S.; Hui, H.; Kappes, J.C.; Wu, X.; Salazar-Gonzalez, J.F.; Salazar, M.G.; Kilby, J.M.; Saag, M.S.; et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422, 307-312.
40. Ying, H.; Ji, X.; Hart, M.L.; Gupta, K.; Saifuddin, M.; Zariffard, M.R.; Spear, G.T. Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization. AIDS Res. Hum. Retrovir. 2004, 20, 327-335.
41. Senaldi, G.; Davies, E.T.; Mahalingam, M.; Lu, J.; Pozniak, A.; Peakman, M.; Reid, K.B.; Vergani, D. Circulating levels of mannose binding protein in human immunodeficiency virus infection. J. Infect. 1995, 31, 145-148.
42. Jack, D.L.; Lee, M.E.; Turner, M.W.; Klein, N.J.; Read, R.C. Mannose-binding lectin enhances phagocytosis and killing of Neisseria meningitidis by human macrophages. J. Leukoc. Biol. 2005, 77, 328-336.
43. Pagh, R.; Duus, K.; Laursen, I.; Hansen, P.R.; Mangor, J.; Thielens, N.; Arlaud, G.J.; Kongerslev, L.; Hojrup, P.; Houen, G. The chaperone and potential mannan-binding lectin (MBL) co-receptor calreticulin interacts with MBL through the binding site for MBL-associated serine proteases. FEBS J. 2008, 275, 515-526.
44. Spear, G.T.; Zariffard, M.R.; Xin, J.; Saifuddin, M. Inhibition of DC-SIGN-mediated trans infection of T cells by mannose-binding lectin. Immunology 2003, 110, 80-85.
45. Chang, W.C.; White, M.R.; Moyo, P.; McClear, S.; Thiel, S.; Hartshorn, K.L.; Takahashi, K. Lack of the pattern recognition molecule mannose-binding lectin increases susceptibility to influenza A virus infection. BMC Immunol. 2010, 11, 64.
46. Kase, T.; Suzuki, Y.; Kawai, T.; Sakamoto, T.; Ohtani, K.; Eda, S.; Maeda, A.; Okuno, Y.; Kurimura, T.; Wakamiya, N. Human mannan-binding lectin inhibits the infection of influenza A virus without complement. Immunology 1999, 97, 385-392.
47. Brown, K.S.; Keogh, M.J.; Owsianka, A.M.; Adair, R.; Patel, A.H.; Arnold, J.N.; Ball, J.K.; Sim, R.B.; Tarr, A.W.; Hickling, T.P. Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry. Protein Cell 2010, 1, 664-674.
48. Ip, W.K.; Chan, K.H.; Law, H.K.; Tso, G.H.; Kong, E.K.; Wong, W.H.; To, Y.F.; Yung, R.W.; Chow, E.Y.; Au, K.L.; et al. Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J. Infect. Dis. 2005, 191, 1697-1704.
49. Zhou, Y.; Lu, K.; Pfefferle, S.; Bertram, S.; Glowacka, I.; Drosten, C.; Pohlmann, S.; Simmons, G. A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms. J. Virol. 2010, 84, 8753-8764.
50. Avirutnan, P.; Hauhart, R.E.; Marovich, M.A.; Garred, P.; Atkinson, J.P.; Diamond, M.S. Complement-mediated neutralization of dengue virus requires mannose-binding lectin. MBio 2011, 2, doi:10.1128/mBio.00276-11.
51. Fuchs, A.; Lin, T.Y.; Beasley, D.W.; Stover, C.M.; Schwaeble, W.J.; Pierson, T.C.; Diamond, M.S. Direct complement restriction of flavivirus infection requires glycan recognition by mannose-binding lectin. Cell Host Microbe 2010, 8, 186-195.
52. El Saadany, S.A.; Ziada, D.H.; Farrag, W.; Hazaa, S. Fibrosis severity and mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex in HCV-infected patients. Arab. J. Gastroenterol. 2011, 12, 68-73.
53. Michelow, I.C.; Lear, C.; Scully, C.; Prugar, L.I.; Longley, C.B.; Yantosca, L.M.; Ji, X.; Karpel, M.; Brudner, M.; Takahashi, K.; et al. High-dose mannose-binding lectin therapy for Ebola virus infection. J. Infect. Dis. 2011, 203, 175-179.
54. Ji, X.; Olinger, G.G.; Aris, S.; Chen, Y.; Gewurz, H.; Spear, G.T. Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J. Gen. Virol. 2005, 86, 2535-2542.
55. Brudner, M.; Karpel, M.; Lear, C.; Chen, L.; Yantosca, L.M.; Scully, C.; Sarraju, A.; Sokolovska, A.; Zariffard, M.R.; Eisen, D.P.; et al. Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors. PLoS One 2013, 8, e60838.
56. Bachis, A.; Aden, S.A.; Nosheny, R.L.; Andrews, P.M.; Mocchetti, I. Axonal transport of human immunodeficiency virus type 1 envelope protein glycoprotein 120 is found in association with neuronal apoptosis. J. Neurosci. 2006, 26, 6771-6780.
57. Teodorof, C.; Divakar, S.; Soontornniyomkij, B.; Achim, C.L.; Kaul, M.; Singh, K.K. Intracellular mannose binding lectin mediates subcellular trafficking of HIV-1 gp120 in neurons. Neurobiol. Dis. 2014, 69, 54-64.
58. Sumiya, M.; Super, M.; Tabona, P.; Levinsky, R.J.; Arai, T.; Turner, M.W.; Summerfield, J.A. Molecular basis of opsonic defect in immunodeficient children. Lancet 1991, 337, 1569-1570.
59. Lipscombe, R.J.; Sumiya, M.; Hill, A.V.; Lau, Y.L.; Levinsky, R.J.; Summerfield, J.A.; Turner, M.W. High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. Hum. Mol. Genet. 1992, 1, 709-715.
60. Madsen, H.O.; Garred, P.; Kurtzhals, J.A.; Lamm, L.U.; Ryder, L.P.; Thiel, S.; Svejgaard, A. A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics 1994, 40, 37-44.
61. Madsen, H.O.; Satz, M.L.; Hogh, B.; Svejgaard, A.; Garred, P. Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J. Immunol. 1998, 161, 3169-3175.
62. Chalmers, J.D.; McHugh, B.J.; Doherty, C.; Smith, M.P.; Govan, J.R.; Kilpatrick, D.C.; Hill, A.T. Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: A prospective study. Lancet Respir. Med. 2013, 1, 224-232.
63. Lipscombe, R.J.; Sumiya, M.; Summerfield, J.A.; Turner, M.W. Distinct physicochemical characteristics of human mannose binding protein expressed by individuals of differing genotype. Immunology 1995, 85, 660-667.
64. Verga Falzacappa, M.V.; Segat, L.; Puppini, B.; Amoroso, A.; Crovella, S. Evolution of the mannose-binding lectin gene in primates. Genes Immun. 2004, 5, 653-661.
65. Garred, P.; Larsen, F.; Seyfarth, J.; Fujita, R.; Madsen, H.O. Mannose-binding lectin and its genetic variants. Genes Immun. 2006, 7, 85-94.
66. Soltani, A.; RahmatiRad, S.; Pourpak, Z.; Alizadeh, Z.; Saghafi, S.; HajiBeigi, B.; Zeidi, M.; Farazmand, A. Polymorphisms and serum level of mannose-binding lectin: An Iranian survey. Iran. J. Allergy Asthma Immunol. 2014, 13, 428-432.
67. Lee, S.G.; Yum, J.S.; Moon, H.M.; Kim, H.J.; Yang, Y.J.; Kim, H.L.; Yoon, Y.; Lee, S.; Song, K. Analysis of mannose-binding lectin 2 (MBL2) genotype and the serum protein levels in the Korean population. Mol. Immunol. 2005, 42, 969-977.
68. Thiel, S.; Bjerke, T.; Hansen, D.; Poulsen, L.K.; Schiotz, P.O.; Jensenius, J.C. Ontogeny of human mannan-binding protein, a lectin of the innate immune system. Pediatr. Allergy Immunol. 1995, 6, 20-23.
69. Roos, A.; Garred, P.; Wildenberg, M.E.; Lynch, N.J.; Munoz, J.R.; Zuiverloon, T.C.; Bouwman, L.H.; Schlagwein, N.; Fallaux van den Houten, F.C.; Faber-Krol, M.C.; et al. Antibody-mediated activation of the classical pathway of complement may compensate for mannose-binding lectin deficiency. Eur. J. Immunol. 2004, 34, 2589-2598.
70. Garred, P.; Madsen, H.O.; Balslev, U.; Hofmann, B.; Pedersen, C.; Gerstoft, J.; Svejgaard, A. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997, 349, 236-240.
71. Prohaszka, Z.; Thiel, S.; Ujhelyi, E.; Szlavik, J.; Banhegyi, D.; Fust, G. Mannan-binding lectin serum concentrations in HIV-infected patients are influenced by the stage of disease. Immunol. Lett. 1997, 58, 171-175.
72. Catano, G.; Agan, B.K.; Kulkarni, H.; Telles, V.; Marconi, V.C.; Dolan, M.J.; Ahuja, S.K. Independent effects of genetic variations in mannose-binding lectin influence the course of HIV disease: The advantage of heterozygosity for coding mutations. J. Infect. Dis. 2008, 198, 72-80.
73. Vallinoto, A.C.; Menezes-Costa, M.R.; Alves, A.E.; Machado, L.F.; de Azevedo, V.N.; Souza, L.L.; Ishak Mde, O.; Ishak, R. Mannose-binding lectin gene polymorphism and its impact on human immunodeficiency virus 1 infection. Mol. Immunol. 2006, 43, 1358-1362.
74. Boniotto, M.; Crovella, S.; Pirulli, D.; Scarlatti, G.; Spano, A.; Vatta, L.; Zezlina, S.; Tovo, P.A.; Palomba, E.; Amoroso, A. Polymorphisms in the MBL2 promoter correlated with risk of HIV-1 vertical transmission and AIDS progression. Genes Immun. 2000, 1, 346-348.
75. Vallinoto, A.C.; Muto, N.A.; Alves, A.E.; Machado, L.F.; Azevedo, V.N.; Souza, L.L.; Ishak, M.O.; Ishak, R. Characterization of polymorphisms in the mannose-binding lectin gene promoter among human immunodeficiency virus 1 infected subjects. Mem. Inst. Oswaldo Cruz. 2008, 103, 645-649.
76. Malik, S.; Arias, M.; di Flumeri, C.; Garcia, L.F.; Schurr, E. Absence of association between mannose-binding lectin gene polymorphisms and HIV-1 infection in a Colombian population. Immunogenetics 2003, 55, 49-52.
77. Lian, Y.C.; Della-Negra, M.; Rutz, R.; Ferriani, V.; de Moraes Vasconcelos, D.; da Silva Duarte, A.J.; Kirschfink, M.; Grumach, A.S. Immunological analysis in paediatric HIV patients at different stages of the disease. Scand. J. Immunol. 2004, 60, 615-624.
78. Nielsen, S.L.; Andersen, P.L.; Koch, C.; Jensenius, J.C.; Thiel, S. The level of the serum opsonin, mannan-binding protein in HIV-1 antibody-positive patients. Clin. Exp. Immunol. 1995, 100, 219-222.
79. Heggelund, L.; Mollnes, T.E.; Ueland, T.; Christophersen, B.; Aukrust, P.; Froland, S.S. Mannose-binding lectin in HIV infection: Relation to disease progression and highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 2003, 32, 354-361.
80. Maas, J.; de Roda Husman, A.M.; Brouwer, M.; Krol, A.; Coutinho, R.; Keet, I.; van Leeuwen, R.; Schuitemaker, H. Presence of the variant mannose-binding lectin alleles associated with slower progression to AIDS. Amsterdam Cohort Study. AIDS 1998, 12, 2275-2280.
81. Chong, W.P.; To, Y.F.; Ip, W.K.; Yuen, M.F.; Poon, T.P.; Wong, W.H.; Lai, C.L.; Lau, Y.L. Mannose-binding lectin in chronic hepatitis B virus infection. Hepatology 2005, 42, 1037-1045.
82. Halla, M.C.; do Carmo, R.F.; Silva Vasconcelos, L.R.; Pereira, L.B.; Moura, P.; de Siqueira, E.R.; Pereira, L.M.; Mendonca Cavalcanti Mdo, S. Association of hepatitis C virus infection and liver fibrosis severity with the variants alleles of MBL2 gene in a Brazilian population. Hum. Immunol. 2010, 71, 883-887.
83. Alves Pedroso, M.L.; Boldt, A.B.; Pereira-Ferrari, L.; Steffensen, R.; Strauss, E.; Jensenius, J.C.; Ioshii, S.O.; Messias-Reason, I. Mannan-binding lectin MBL2 gene polymorphism in chronic hepatitis C: Association with the severity of liver fibrosis and response to interferon therapy. Clin. Exp. Immunol. 2008, 152, 258-264.
84. Alves, A.E.; Hermes, R.B.; Tamegao-Lopes, B.; Machado, L.F.; Azevedo, V.N.; Ishak, M.O.; Ishak, R.; Lemos, J.A.; Vallinoto, A.C. Polymorphism in the promoter region of the mannose-binding lectin gene among human T-cell lymphotropic virus infected subjects. Mem. Inst. Oswaldo Cruz. 2007, 102, 991-994.
85. Kwakkel-van Erp, J.M.; Paantjens, A.W.; van Kessel, D.A.; Grutters, J.C.; van den Bosch, J.M.; van de Graaf, E.A.; Otten, H.G. Mannose-binding lectin deficiency linked to cytomegalovirus (CMV) reactivation and survival in lung transplantation. Clin. Exp. Immunol. 2011, 165, 410-416.
86. De Rooij, B.J.; van der Beek, M.T.; van Hoek, B.; Vossen, A.C.; Rogier Ten Hove, W.; Roos, A.; Schaapherder, A.F.; Porte, R.J.; van der Reijden, J.J.; Coenraad, M.J.; et al. Mannose-binding lectin and ficolin-2 gene polymorphisms predispose to cytomegalovirus (re)infection after orthotopic liver transplantation. J. Hepatol. 2011, 55, 800-807.
87. Thomas, H.C.; Foster, G.R.; Sumiya, M.; McIntosh, D.; Jack, D.L.; Turner, M.W.; Summerfield, J.A. Mutation of gene of mannose-binding protein associated with chronic hepatitis B viral infection. Lancet 1996, 348, 1417-1419.
88. Xu, H.D.; Zhao, M.F.; Wan, T.H.; Song, G.Z.; He, J.L.; Chen, Z. Association between Mannose-binding lectin gene polymorphisms and hepatitis B virus infection: A meta-analysis. PLoS One 2013, 8, e75371.
89. Koutsounaki, E.; Goulielmos, G.N.; Koulentaki, M.; Choulaki, C.; Kouroumalis, E.; Galanakis, E. Mannose-binding lectin MBL2 gene polymorphisms and outcome of hepatitis C virus-infected patients. J. Clin. Immunol. 2008, 28, 495-500.
90. Abdelaal, A.; Mossad, N.; Abdel Hafez, H.; Elsayed, N. Mannose-binding lectin exon 1 polymorphisms in Egyptian patients with chronic hepatitis C virus infection. Comp. Clin. Pathol. 2014, 23, 1339-1342.
91. Yuen, M.F.; Lau, C.S.; Lau, Y.L.; Wong, W.M.; Cheng, C.C.; Lai, C.L. Mannose binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection. Hepatology 1999, 29, 1248-1251.
92. Pontes, G.S.; Tamegao-Lopes, B.; Machado, L.F.; Azevedo, V.N.; Ishak, M.O.; Ishak, R.; Lemos, J.A.; Vallinoto, A.C. Characterization of mannose-binding lectin gene polymorphism among human T-cell lymphotropic virus 1 and 2-infected asymptomatic subjects. Hum. Immunol. 2005, 66, 892-896.
93. Ammitzbøll, C.G.; Kjaer, T.R.; Steffensen, R.; Stengaard-Pedersen, K.; Nielsen, H.J.; Thiel, S.; Bogsted, M.; Jensenius, J.C. Non-synonymous polymorphisms in the FCN1 gene determine ligand-binding ability and serum levels of M-ficolin. PLoS One 2012, 7, e50585.
94. Hummelshøj, T.; Munthe-Fog, L.; Madsen, H.O.; Garred, P. Functional SNPs in the human ficolin (FCN) genes reveal distinct geographical patterns. Mol. Immunol. 2008, 45, 2508-2520.
95. Hoang, T.V.; Toan, N.L.; Song le, H.; Ouf, E.A.; Bock, C.T.; Kremsner, P.G.; Kun, J.F.; Velavan, T.P. Ficolin-2 levels and FCN2 haplotypes influence hepatitis B infection outcome in Vietnamese patients. PLoS One 2011, 6, e28113.
96. Ma, Y.J.; Doni, A.; Hummelshoj, T.; Honore, C.; Bastone, A.; Mantovani, A.; Thielens, N.M.; Garred, P. Synergy between ficolin-2 and pentraxin 3 boosts innate immune recognition and complement deposition. J. Biol. Chem. 2009, 284, 28263-28275.
97. Munthe-Fog, L.; Hummelshoj, T.; Ma, Y.J.; Hansen, B.E.; Koch, C.; Madsen, H.O.; Skjodt, K.; Garred, P. Characterization of a polymorphism in the coding sequence of FCN3 resulting in a Ficolin-3 (Hakata antigen) deficiency state. Mol. Immunol. 2008, 45, 2660-2666.
98. Munthe-Fog, L.; Hummelshoj, T.; Honore, C.; Madsen, H.O.; Permin, H.; Garred, P. Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency. N. Engl. J. Med. 2009, 360, 2637-2644.
99. Schlapbach, L.J.; Thiel, S.; Kessler, U.; Ammann, R.A.; Aebi, C.; Jensenius, J.C. Congenital H-ficolin deficiency in premature infants with severe necrotising enterocolitis. Gut 2011, 60, 1438-1439.
100. Wang, L.; Chen, R.F.; Liu, J.W.; Lee, I.K.; Lee, C.P.; Kuo, H.C.; Huang, S.K.; Yang, K.D. DC-SIGN (CD209) Promoter -336 A/G polymorphism is associated with dengue hemorrhagic fever and correlated to DC-SIGN expression and immune augmentation. PLoS Negl. Trop. Dis. 2011, 5, e934.
101. Sakuntabhai, A.; Turbpaiboon, C.; Casademont, I.; Chuansumrit, A.; Lowhnoo, T.; Kajaste-Rudnitski, A.; Kalayanarooj, S.M.; Tangnararatchakit, K.; Tangthawornchaikul, N.; Vasanawathana, S.; et al. A variant in the CD209 promoter is associated with severity of dengue disease. Nat. Genet. 2005, 37, 507-513.
102. Oliveira, L.F.; Lima, C.P.; Azevedo Rdo, S.; Mendonca, D.S.; Rodrigues, S.G.; Carvalho, V.L.; Pinto, E.V.; Maia, A.L.; Maia, M.H.; Vasconcelos, J.M.; et al. Polymorphism of DC-SIGN (CD209) promoter in association with clinical symptoms of dengue fever. Viral Immunol. 2014, 27, 245-249.
103. Ryan, E.J.; Dring, M.; Ryan, C.M.; McNulty, C.; Stevenson, N.J.; Lawless, M.W.; Crowe, J.; Nolan, N.; Hegarty, J.E.; O'Farrelly, C. Variant in CD209 promoter is associated with severity of liver disease in chronic hepatitis C virus infection. Hum. Immunol. 2010, 71, 829-832.
104. Boily-Larouche, G.; Milev, M.P.; Zijenah, L.S.; Labbe, A.C.; Zannou, D.M.; Humphrey, J.H.; Ward, B.J.; Poudrier, J.; Mouland, A.J.; Cohen, E.A.; et al. Naturally-occurring genetic variants in human DC-SIGN increase HIV-1 capture, cell-transfer and risk of mother-to-child transmission. PLoS One 2012, 7, e40706.
105. Martin, M.P.; Lederman, M.M.; Hutcheson, H.B.; Goedert, J.J.; Nelson, G.W.; van Kooyk, Y.; Detels, R.; Buchbinder, S.; Hoots, K.; Vlahov, D.; et al. Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection. J. Virol. 2004, 78, 14053-14056.
106. Da Silva, R.C.; Segat, L.; Zanin, V.; Arraes, L.C.; Crovella, S. Polymorphisms in DC-SIGN and L-SIGN genes are associated with HIV-1 vertical transmission in a Northeastern Brazilian population. Hum. Immunol. 2012, 73, 1159-1165.
107. Chan, K.Y.; Xu, M.S.; Ching, J.C.; So, T.M.; Lai, S.T.; Chu, C.M.; Yam, L.Y.; Wong, A.T.; Chung, P.H.; Chan, V.S.; et al. CD209 (DC-SIGN) -336A>G promoter polymorphism and severe acute respiratory syndrome in Hong Kong Chinese. Hum. Immunol. 2010, 71, 702-707.
108. Kagone, T.S.; Bisseye, C.; Meda, N.; Testa, J.; Pietra, V.; Kania, D.; Yonli, A.T.; Compaore, T.R.; Nikiema, J.B.; de Souza, C.; et al. A variant of DC-SIGN gene promoter associated with resistance to HIV-1 in serodiscordant couples in Burkina Faso. Asian Pac. J. Trop. Med. 2014, 7S1, S93-S96.
109. Eisen, D.P.; Marshall, C.; Dean, M.M.; Sasadeusz, J.; Richards, M.; Buising, K.; Cheng, A.; Johnson, P.D.; Barr, I.G.; McBryde, E.S. No association between mannose-binding lectin deficiency and H1N1 2009 infection observed during the first season of this novel pandemic influenza virus. Hum. Immunol. 2011, 72, 1091-1094.
110. Brown, E.E.; Zhang, M.; Zarin-Pass, R.; Bernig, T.; Tseng, F.C.; Xiao, N.; Yeager, M.; Edlin, B.R.; Chanock, S.J.; O'Brien, T.R. MBL2 and hepatitis C virus infection among injection drug users. BMC Infect. Dis. 2008, 8, 57.
111. Vallinoto, A.C.; da Silva, R.F.; Hermes, R.B.; Amaral, I.S.; Miranda, E.C.; Barbosa, M.S.; Moia Lde, J.; Conde, S.R.; Soares Mdo, C.; Lemos, J.A.; et al. Mannose-binding lectin gene polymorphisms are not associated with susceptibility to hepatitis C virus infection in the Brazilian Amazon region. Hum. Immunol. 2009, 70, 754-757.
112. Esmat, S.; Omran, D.; Sleem, G.A.; Rashed, L. Serum mannan-binding lectin in egyptian patients with chronic hepatitis C: Its relation to disease progression and response to treatment. Hepat. Mon. 2012, 12, 259-264.
113. Wu, Y.; Zhou, Q.; Wang, H.; Tian, T.; Zhu, Q.; Wang, H.; Bai, X.; Yang, X.; Wang, Z.; Dong, M. Potential role of mannose-binding lectin in intrauterine transmission of hepatitis B virus. Jpn. J. Infect. Dis. 2013, 66, 391-393.
114. Höhler, T.; Wunschel, M.; Gerken, G.; Schneider, P.M.; Meyer zum Buschenfelde, K.H.; Rittner, C. No association between mannose-binding lectin alleles and susceptibility to chronic hepatitis B virus infection in German patients. Exp. Clin. Immunogenet. 1998, 15, 130-133.
115. Endo, Y.; Sato, Y.; Matsushita, M.; Fujita, T. Cloning and characterization of the human lectin P35 gene and its related gene. Genomics 1996, 36, 515-521.
116. Ichijo, H.; Ronnstrand, L.; Miyagawa, K.; Ohashi, H.; Heldin, C.H.; Miyazono, K. Purification of transforming growth factor-beta 1 binding proteins from porcine uterus membranes. J. Biol. Chem. 1991, 266, 22459-22464.
117. Lu, J.; Le, Y.; Kon, O.L.; Chan, J.; Lee, S.H. Biosynthesis of human ficolin, an Escherichia coli-binding protein, by monocytes: Comparison with the synthesis of two macrophage-specific proteins, C1q and the mannose receptor. Immunology 1996, 89, 289-294.
118. Sugimoto, R.; Yae, Y.; Akaiwa, M.; Kitajima, S.; Shibata, Y.; Sato, H.; Hirata, J.; Okochi, K.; Izuhara, K.; Hamasaki, N. Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family. J. Biol. Chem. 1998, 273, 20721-20727.
119. Kenjo, A.; Takahashi, M.; Matsushita, M.; Endo, Y.; Nakata, M.; Mizuochi, T.; Fujita, T. Cloning and characterization of novel ficolins from the solitary ascidian, Halocynthia roretzi. J. Biol. Chem. 2001, 276, 19959-19965.
120. Lynch, N.J.; Khan, S.U.; Stover, C.M.; Sandrini, S.M.; Marston, D.; Presanis, J.S.; Schwaeble, W.J. Composition of the lectin pathway of complement in Gallus gallus: Absence of mannan-binding lectin-associated serine protease-1 in birds. J. Immunol. 2005, 174, 4998-5006.
121. Hummelshøj, T.; Nissen, J.; Munthe-Fog, L.; Koch, C.; Bertelsen, M.F.; Garred, P. Allelic lineages of the ficolin genes (FCNs) are passed from ancestral to descendant primates. PLoS One 2011, 6, e28187.
122. Ichijo, H.; Hellman, U.; Wernstedt, C.; Gonez, L.J.; Claesson-Welsh, L.; Heldin, C.H.; Miyazono, K. Molecular cloning and characterization of ficolin, a multimeric protein with fibrinogen- and collagen-like domains. J. Biol. Chem. 1993, 268, 14505-14513.
123. Garred, P.; Honore, C.; Ma, Y.J.; Rorvig, S.; Cowland, J.; Borregaard, N.; Hummelshoj, T. The genetics of ficolins. J. Innate Immun. 2010, 2, 3-16.
124. Hummelshøj, T.; Thielens, N.M.; Madsen, H.O.; Arlaud, G.J.; Sim, R.B.; Garred, P. Molecular organization of human Ficolin-2. Mol. Immunol. 2007, 44, 401-411.
125. Matsushita, M.; Endo, Y.; Taira, S.; Sato, Y.; Fujita, T.; Ichikawa, N.; Nakata, M.; Mizuochi, T. A novel human serum lectin with collagen- and fibrinogen-like domains that functions as an opsonin. J. Biol. Chem. 1996, 271, 2448-2454.
126. Lacroix, M.; Dumestre-Perard, C.; Schoehn, G.; Houen, G.; Cesbron, J.Y.; Arlaud, G.J.; Thielens, N.M. Residue Lys57 in the collagen-like region of human L-ficolin and its counterpart Lys47 in H-ficolin play a key role in the interaction with the mannan-binding lectin-associated serine proteases and the collectin receptor calreticulin. J. Immunol. 2009, 182, 456-465.
127. Weis, W.I.; Drickamer, K. Trimeric structure of a C-type mannose-binding protein. Structure 1994, 2, 1227-1240.
128. Ohashi, T.; Erickson, H.P. The disulfide bonding pattern in ficolin multimers. J. Biol. Chem. 2004, 279, 6534-6539.
129. Akaiwa, M.; Yae, Y.; Sugimoto, R.; Suzuki, S.O.; Iwaki, T.; Izuhara, K.; Hamasaki, N. Hakata antigen, a new member of the ficolin/opsonin p35 family, is a novel human lectin secreted into bronchus/alveolus and bile. J. Histochem. Cytochem. 1999, 47, 777-786.
130. Liu, Y.; Endo, Y.; Iwaki, D.; Nakata, M.; Matsushita, M.; Wada, I.; Inoue, K.; Munakata, M.; Fujita, T. Human M-ficolin is a secretory protein that activates the lectin complement pathway. J. Immunol. 2005, 175, 3150-3156.
131. Schlapbach, L.J.; Aebi, C.; Hansen, A.G.; Hirt, A.; Jensenius, J.C.; Ammann, R.A. H-ficolin serum concentration and susceptibility to fever and neutropenia in paediatric cancer patients. Clin. Exp. Immunol. 2009, 157, 83-89.
132. Kilpatrick, D.C.; Fujita, T.; Matsushita, M. P35, an opsonic lectin of the ficolin family, in human blood from neonates, normal adults, and recurrent miscarriage patients. Immunol. Lett. 1999, 67, 109-112.
133. Munthe-Fog, L.; Hummelshoj, T.; Hansen, B.E.; Koch, C.; Madsen, H.O.; Skjodt, K.; Garred, P. The impact of FCN2 polymorphisms and haplotypes on the Ficolin-2 serum levels. Scand. J. Immunol. 2007, 65, 383-392.
134. Wittenborn, T.; Thiel, S.; Jensen, L.; Nielsen, H.J.; Jensenius, J.C. Characteristics and biological variations of M-ficolin, a pattern recognition molecule, in plasma. J. Innate Immun. 2010, 2, 167-180.
135. Garlatti, V.; Belloy, N.; Martin, L.; Lacroix, M.; Matsushita, M.; Endo, Y.; Fujita, T.; Fontecilla-Camps, J.C.; Arlaud, G.J.; Thielens, N.M.; et al. Structural insights into the innate immune recognition specificities of L- and H-ficolins. EMBO J. 2007, 26, 623-633.
136. Vassal-Stermann, E.; Lacroix, M.; Gout, E.; Laffly, E.; Pedersen, C.M.; Martin, L.; Amoroso, A.; Schmidt, R.R.; Zahringer, U.; Gaboriaud, C.; et al. Human L-Ficolin Recognizes Phosphocholine Moieties of Pneumococcal Teichoic Acid. J. Immunol. 2014, doi:10.4049/jimmunol.1400127.
137. Luo, F.; Sun, X.; Wang, Y.; Wang, Q.; Wu, Y.; Pan, Q.; Fang, C.; Zhang, X.L. Ficolin-2 Defends against Virulent Mycobacteria Tuberculosis Infection in Vivo, and Its Insufficiency Is Associated with Infection in Humans. PLoS One 2013, 8, e73859.
138. Jensen, M.L.; Honore, C.; Hummelshoj, T.; Hansen, B.E.; Madsen, H.O.; Garred, P. Ficolin-2 recognizes DNA and participates in the clearance of dying host cells. Mol. Immunol. 2007, 44, 856-865.
139. Hamed, M.R.; Brown, R.J.; Zothner, C.; Urbanowicz, R.A.; Mason, C.P.; Krarup, A.; McClure, C.P.; Irving, W.L.; Ball, J.K.; Harris, M.; et al. Recombinant human L-ficolin directly neutralizes hepatitis C virus entry. J. Innate Immun. 2014, 6, 676-684.
140. Keirstead, N.D.; Lee, C.; Yoo, D.; Brooks, A.S.; Hayes, M.A. Porcine plasma ficolin binds and reduces infectivity of porcine reproductive and respiratory syndrome virus (PRRSV) in vitro. Antivir. Res. 2008, 77, 28-38.
141. Liu, J.; Ali, M.A.; Shi, Y.; Zhao, Y.; Luo, F.; Yu, J.; Xiang, T.; Tang, J.; Li, D.; Hu, Q.; et al. Specifically binding of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell. Mol. Immunol. 2009, 6, 235-244.
142. Pan, Q.; Chen, H.; Wang, F.; Jeza, V.T.; Hou, W.; Zhao, Y.; Xiang, T.; Zhu, Y.; Endo, Y.; Fujita, T.; et al. L-ficolin binds to the glycoproteins hemagglutinin and neuraminidase and inhibits influenza A virus infection both in vitro and in vivo. J. Innate Immun. 2012, 4, 312-324.
143. Zhao, Y.; Ren, Y.; Zhang, X.; Zhao, P.; Tao, W.; Zhong, J.; Li, Q.; Zhang, X.L. Ficolin-2 inhibits hepatitis C virus infection, whereas apolipoprotein E3 mediates viral immune escape. J. Immunol. 2014, 193, 783-796.
144. Verma, A.; White, M.; Vathipadiekal, V.; Tripathi, S.; Mbianda, J.; Ieong, M.; Qi, L.; Taubenberger, J.K.; Takahashi, K.; Jensenius, J.C.; et al. Human H-ficolin inhibits replication of seasonal and pandemic influenza A viruses. J. Immunol. 2012, 189, 2478-2487.
145. Ren, Y.; Ding, Q.; Zhang, X. Ficolins and infectious diseases. Virol. Sin. 2014, 29, 25-32.
146. Honore, C.; Rorvig, S.; Hummelshoj, T.; Skjoedt, M.O.; Borregaard, N.; Garred, P. Tethering of Ficolin-1 to cell surfaces through recognition of sialic acid by the fibrinogen-like domain. J. Leukoc. Biol. 2010, 88, 145-158.
147. Zhang, J.; Yang, L.; Ang, Z.; Yoong, S.L.; Tran, T.T.; Anand, G.S.; Tan, N.S.; Ho, B.; Ding, J.L. Secreted M-ficolin anchors onto monocyte transmembrane G protein-coupled receptor 43 and cross talks with plasma C-reactive protein to mediate immune signaling and regulate host defense. J. Immunol. 2010, 185, 6899-6910.
148. Kjaer, T.R.; Hansen, A.G.; Sorensen, U.B.; Nielsen, O.; Thiel, S.; Jensenius, J.C. Investigations on the pattern recognition molecule M-ficolin: Quantitative aspects of bacterial binding and leukocyte association. J. Leukoc. Biol. 2011, 90, 425-437.
149. Hummelshøj, T.; Munthe-Fog, L.; Madsen, H.O.; Fujita, T.; Matsushita, M.; Garred, P. Polymorphisms in the FCN2 gene determine serum variation and function of Ficolin-2. Hum. Mol. Genet. 2005, 14, 1651-1658.
150. Herpers, B.L.; Immink, M.M.; de Jong, B.A.; van Velzen-Blad, H.; de Jongh, B.M.; van Hannen, E.J. Coding and non-coding polymorphisms in the lectin pathway activator L-ficolin gene in 188 Dutch blood bank donors. Mol. Immunol. 2006, 43, 851-855.
151. Garred, P.; Honore, C.; Ma, Y.J.; Munthe-Fog, L.; Hummelshoj, T. MBL2, FCN1, FCN2 and FCN3-The genes behind the initiation of the lectin pathway of complement. Mol. Immunol. 2009, 46, 2737-2744.
152. Assaf, A.; Hoang, T.V.; Faik, I.; Aebischer, T.; Kremsner, P.G.; Kun, J.F.; Velavan, T.P. Genetic evidence of functional ficolin-2 haplotype as susceptibility factor in cutaneous leishmaniasis. PLoS One 2012, 7, e34113.
153. De Messias-Reason, I.; Kremsner, P.G.; Kun, J.F. Functional haplotypes that produce normal ficolin-2 levels protect against clinical leprosy. J. Infect. Dis. 2009, 199, 801-804.
154. Chalmers, J.D.; Kilpatrick, D.C.; McHugh, B.J.; Smith, M.P.; Govan, J.R.W.; Doherty, C.; Matsushita, M.; Hart, S.P.; Sethi, T.; Hill, A.T. T2 Single nucleotide polymorphisms in the ficolin-2 gene predispose to Pseudomonas aeruginosa infection and disease severity in non-cystic fibrosis bronchiectasis. Thorax 2011, 66, A1-A2.
155. Messias-Reason, I.J.; Schafranski, M.D.; Kremsner, P.G.; Kun, J.F. Ficolin 2 (FCN2) functional polymorphisms and the risk of rheumatic fever and rheumatic heart disease. Clin. Exp. Immunol. 2009, 157, 395-399.
156. Chapman, S.J.; Vannberg, F.O.; Khor, C.C.; Segal, S.; Moore, C.E.; Knox, K.; Day, N.P.; Davies, R.J.; Crook, D.W.; Hill, A.V. Functional polymorphisms in the FCN2 gene are not associated with invasive pneumococcal disease. Mol. Immunol. 2007, 44, 3267-3270.
157. Ruskamp, J.M.; Hoekstra, M.O.; Postma, D.S.; Kerkhof, M.; Bottema, R.W.; Koppelman, G.H.; Rovers, M.M.; Wijga, A.H.; de Jongste, J.C.; Brunekreef, B.; et al. Exploring the role of polymorphisms in ficolin genes in respiratory tract infections in children. Clin. Exp. Immunol. 2009, 155, 433-440.
158. Boldt, A.B.; Sanchez, M.I.; Stahlke, E.R.; Steffensen, R.; Thiel, S.; Jensenius, J.C.; Prevedello, F.C.; Mira, M.T.; Kun, J.F.; Messias-Reason, I.J. Susceptibility to leprosy is associated with M-ficolin polymorphisms. J. Clin. Immunol. 2013, 33, 210-219.
159. Vander Cruyssen, B.; Nuytinck, L.; Boullart, L.; Elewaut, D.; Waegeman, W.; van Thielen, M.; de Meester, E.; Lebeer, K.; Rossau, R.; de Keyser, F. Polymorphisms in the ficolin 1 gene (FCN1) are associated with susceptibility to the development of rheumatoid arthritis. Rheumatology (Oxford) 2007, 46, 1792-1795.
160. Urban, T.J.; Thompson, A.J.; Bradrick, S.S.; Fellay, J.; Schuppan, D.; Cronin, K.D.; Hong, L.; McKenzie, A.; Patel, K.; Shianna, K.V.; et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010, 52, 1888-1896.
161. McCarthy, J.J.; Li, J.H.; Thompson, A.; Suchindran, S.; Lao, X.Q.; Patel, K.; Tillmann, H.L.; Muir, A.J.; McHutchison, J.G. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010, 138, 2307-2314.
162. Hu, Y.L.; Luo, F.L.; Fu, J.L.; Chen, T.L.; Wu, S.M.; Zhou, Y.D.; Zhang, X.L. Early increased ficolin-2 concentrations are associated with severity of liver inflammation and efficacy of anti-viral therapy in chronic hepatitis C patients. Scand. J. Immunol. 2013, 77, 144-150.
163. Cedzynski, M.; Atkinson, A.P.; St Swierzko, A.; MacDonald, S.L.; Szala, A.; Zeman, K.; Buczylko, K.; Bak-Romaniszyn, L.; Wiszniewska, M.; Matsushita, M.; et al. L-ficolin (ficolin-2) insufficiency is associated with combined allergic and infectious respiratory disease in children. Mol. Immunol. 2009, 47, 415-419.
164. Faik, I.; Oyedeji, S.I.; Idris, Z.; de Messias-Reason, I.J.; Lell, B.; Kremsner, P.G.; Kun, J.F. Ficolin-2 levels and genetic polymorphisms of FCN2 in malaria. Hum. Immunol. 2011, 72, 74-79.
165. Ma, Y.J.; Doni, A.; Skjoedt, M.O.; Honore, C.; Arendrup, M.; Mantovani, A.; Garred, P. Heterocomplexes of mannose-binding lectin and the pentraxins PTX3 or serum amyloid P component trigger cross-activation of the complement system. J. Biol. Chem. 2011, 286, 3405-3417.
166. Panda, S.; Zhang, J.; Tan, N.S.; Ho, B.; Ding, J.L. Natural IgG antibodies provide innate protection against ficolin-opsonized bacteria. EMBO J. 2013, 32, 2905-2919.
167. Panda, S.; Zhang, J.; Yang, L.; Anand, G.S.; Ding, J.L. Molecular interaction between natural IgG and ficolin - Mechanistic insights on adaptive-innate immune crosstalk. Sci. Rep. 2014, 4, 3675.
168. Gout, E.; Moriscot, C.; Doni, A.; Dumestre-Perard, C.; Lacroix, M.; Perard, J.; Schoehn, G.; Mantovani, A.; Arlaud, G.J.; Thielens, N.M. M-ficolin interacts with the long pentraxin PTX3: A novel case of cross-talk between soluble pattern-recognition molecules. J. Immunol. 2011, 186, 5815-5822.
169. Ma, Y.J.; Doni, A.; Romani, L.; Jurgensen, H.J.; Behrendt, N.; Mantovani, A.; Garred, P. Ficolin-1-PTX3 complex formation promotes clearance of altered self-cells and modulates IL-8 production. J. Immunol. 2013, 191, 1324-1333.
170. Zhang, J.; Koh, J.; Lu, J.; Thiel, S.; Leong, B.S.; Sethi, S.; He, C.Y.; Ho, B.; Ding, J.L. Local inflammation induces complement crosstalk which amplifies the antimicrobial response. PLoS Pathog. 2009, 5, e1000282.
171. Zhang, J.; Yang, L.; Anand, G.S.; Ho, B.; Ding, J.L. Pathophysiological condition changes the conformation of a flexible FBG-related protein, switching it from pathogen-recognition to host-interaction. Biochimie 2011, 93, 1710-1719.
172. Geijtenbeek, T.B.; Kwon, D.S.; Torensma, R.; van Vliet, S.J.; van Duijnhoven, G.C.; Middel, J.; Cornelissen, I.L.; Nottet, H.S.; KewalRamani, V.N.; Littman, D.R.; et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000, 100, 587-597.
173. Ganguly, D.; Haak, S.; Sisirak, V.; Reizis, B. The role of dendritic cells in autoimmunity. Nat. Rev. Immunol. 2013, 13, 566-577.
174. Geijtenbeek, T.B.; Torensma, R.; van Vliet, S.J.; van Duijnhoven, G.C.; Adema, G.J.; van Kooyk, Y.; Figdor, C.G. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000, 100, 575-585.
175. Mitchell, D.A.; Fadden, A.J.; Drickamer, K. A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands. J. Biol. Chem. 2001, 276, 28939-28945.
176. Manzo, C.; Torreno-Pina, J.A.; Joosten, B.; Reinieren-Beeren, I.; Gualda, E.J.; Loza-Alvarez, P.; Figdor, C.G.; Garcia-Parajo, M.F.; Cambi, A. The neck region of the C-type lectin DC-SIGN regulates its surface spatiotemporal organization and virus-binding capacity on antigen-presenting cells. J. Biol. Chem. 2012, 287, 38946-38955.
177. Kwon, D.S.; Gregorio, G.; Bitton, N.; Hendrickson, W.A.; Littman, D.R. DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity 2002, 16, 135-144.
178. Soilleux, E.J.; Barten, R.; Trowsdale, J. DC-SIGN; a related gene, DC-SIGNR; and CD23 form a cluster on 19p13. J. Immunol. 2000, 165, 2937-2942.
179. Baribaud, F.; Pohlmann, S.; Leslie, G.; Mortari, F.; Doms, R.W. Quantitative expression and virus transmission analysis of DC-SIGN on monocyte-derived dendritic cells. J. Virol. 2002, 76, 9135-9142.
180. Pöhlmann, S.; Baribaud, F.; Lee, B.; Leslie, G.J.; Sanchez, M.D.; Hiebenthal-Millow, K.; Munch, J.; Kirchhoff, F.; Doms, R.W. DC-SIGN interactions with human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus. J. Virol. 2001, 75, 4664-4672.
181. Lin, G.; Simmons, G.; Pohlmann, S.; Baribaud, F.; Ni, H.; Leslie, G.J.; Haggarty, B.S.; Bates, P.; Weissman, D.; Hoxie, J.A.; et al. Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J. Virol. 2003, 77, 1337-1346.
182. Haase, A.T. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010, 464, 217-223.
183. Xiao, X.; Kinter, A.; Broder, C.C.; Dimitrov, D.S. Interactions of CCR5 and CXCR4 with CD4 and gp120 in human blood monocyte-derived dendritic cells. Exp. Mol. Pathol. 2000, 68, 133-138.
184. Moris, A.; Nobile, C.; Buseyne, F.; Porrot, F.; Abastado, J.P.; Schwartz, O. DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation. Blood 2004, 103, 2648-2654.
185. Smith, A.L.; Ganesh, L.; Leung, K.; Jongstra-Bilen, J.; Jongstra, J.; Nabel, G.J. Leukocyte-specific protein 1 interacts with DC-SIGN and mediates transport of HIV to the proteasome in dendritic cells. J. Exp. Med. 2007, 204, 421-430.
186. Gringhuis, S.I.; van der Vlist, M.; van den Berg, L.M.; den Dunnen, J.; Litjens, M.; Geijtenbeek, T.B. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat. Immunol. 2010, 11, 419-426.
187. Hijazi, K.; Wang, Y.; Scala, C.; Jeffs, S.; Longstaff, C.; Stieh, D.; Haggarty, B.; Vanham, G.; Schols, D.; Balzarini, J.; et al. DC-SIGN increases the affinity of HIV-1 envelope glycoprotein interaction with CD4. PLoS One 2011, 6, e28307.
188. Lee, B.; Leslie, G.; Soilleux, E.; O'Doherty, U.; Baik, S.; Levroney, E.; Flummerfelt, K.; Swiggard, W.; Coleman, N.; Malim, M.; et al. cis Expression of DC-SIGN allows for more efficient entry of human and simian immunodeficiency viruses via CD4 and a coreceptor. J. Virol. 2001, 75, 12028-12038.
189. Miyauchi, K.; Kim, Y.; Latinovic, O.; Morozov, V.; Melikyan, G.B. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 2009, 137, 433-444.
190. Van Montfort, T.; Eggink, D.; Boot, M.; Tuen, M.; Hioe, C.E.; Berkhout, B.; Sanders, R.W. HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation. J. Immunol. 2011, 187, 4676-4685.
191. McDonald, D.; Wu, L.; Bohks, S.M.; KewalRamani, V.N.; Unutmaz, D.; Hope, T.J. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 2003, 300, 1295-1297.
192. Sol-Foulon, N.; Moris, A.; Nobile, C.; Boccaccio, C.; Engering, A.; Abastado, J.P.; Heard, J.M.; van Kooyk, Y.; Schwartz, O. HIV-1 Nef-induced upregulation of DC-SIGN in dendritic cells promotes lymphocyte clustering and viral spread. Immunity 2002, 16, 145-155.
193. Cavrois, M.; Neidleman, J.; Kreisberg, J.F.; Greene, W.C. In vitro derived dendritic cells trans-infect CD4 T cells primarily with surface-bound HIV-1 virions. PLoS Pathog. 2007, 3, e4.
194. Hodges, A.; Sharrocks, K.; Edelmann, M.; Baban, D.; Moris, A.; Schwartz, O.; Drakesmith, H.; Davies, K.; Kessler, B.; McMichael, A.; et al. Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication. Nat. Immunol. 2007, 8, 569-577.
195. Izquierdo-Useros, N.; Lorizate, M.; Puertas, M.C.; Rodriguez-Plata, M.T.; Zangger, N.; Erikson, E.; Pino, M.; Erkizia, I.; Glass, B.; Clotet, B.; et al. Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides. PLoS Biol. 2012, 10, e1001448.
196. Chen, Y.; Hwang, S.L.; Chan, V.S.; Chung, N.P.; Wang, S.R.; Li, Z.; Ma, J.; Lin, C.W.; Hsieh, Y.J.; Chang, K.P.; et al. Binding of HIV-1 gp120 to DC-SIGN promotes ASK-1-dependent activation-induced apoptosis of human dendritic cells. PLoS Pathog. 2013, 9, e1003100.
197. De Witte, L.; de Vries, R.D.; van der Vlist, M.; Yuksel, S.; Litjens, M.; de Swart, R.L.; Geijtenbeek, T.B. DC-SIGN and CD150 have distinct roles in transmission of measles virus from dendritic cells to T-lymphocytes. PLoS Pathog. 2008, 4, e1000049.
198. Alvarez, C.P.; Lasala, F.; Carrillo, J.; Muniz, O.; Corbi, A.L.; Delgado, R. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J. Virol. 2002, 76, 6841-6844.
199. Yang, Z.Y.; Huang, Y.; Ganesh, L.; Leung, K.; Kong, W.P.; Schwartz, O.; Subbarao, K.; Nabel, G.J. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J. Virol. 2004, 78, 5642-5650.
200. Wang, S.F.; Huang, J.C.; Lee, Y.M.; Liu, S.J.; Chan, Y.J.; Chau, Y.P.; Chong, P.; Chen, Y.M. DC-SIGN mediates avian H5N1 influenza virus infection in cis and in trans. Biochem. Biophys. Res. Commun. 2008, 373, 561-566.
201. Pöhlmann, S.; Zhang, J.; Baribaud, F.; Chen, Z.; Leslie, G.J.; Lin, G.; Granelli-Piperno, A.; Doms, R.W.; Rice, C.M.; McKeating, J.A. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J. Virol. 2003, 77, 4070-4080.
202. Halary, F.; Amara, A.; Lortat-Jacob, H.; Messerle, M.; Delaunay, T.; Houles, C.; Fieschi, F.; Arenzana-Seisdedos, F.; Moreau, J.F.; Dechanet-Merville, J. Human cytomegalovirus binding to DC-SIGN is required for dendritic cell infection and target cell trans-infection. Immunity 2002, 17, 653-664.
203. Rappocciolo, G.; Hensler, H.R.; Jais, M.; Reinhart, T.A.; Pegu, A.; Jenkins, F.J.; Rinaldo, C.R. Human herpesvirus 8 infects and replicates in primary cultures of activated B lymphocytes through DC-SIGN. J. Virol. 2008, 82, 4793-4806.
204. Ludwig, I.S.; Lekkerkerker, A.N.; Depla, E.; Bosman, F.; Musters, R.J.; Depraetere, S.; van Kooyk, Y.; Geijtenbeek, T.B. Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation. J. Virol. 2004, 78, 8322-8332.
205. Pöhlmann, S.; Soilleux, E.J.; Baribaud, F.; Leslie, G.J.; Morris, L.S.; Trowsdale, J.; Lee, B.; Coleman, N.; Doms, R.W. DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc. Natl. Acad. Sci. USA 2001, 98, 2670-2675.
206. Marzi, A.; Gramberg, T.; Simmons, G.; Moller, P.; Rennekamp, A.J.; Krumbiegel, M.; Geier, M.; Eisemann, J.; Turza, N.; Saunier, B.; et al. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J. Virol. 2004, 78, 12090-12095.
207. Barreiro, L.B.; Patin, E.; Neyrolles, O.; Cann, H.M.; Gicquel, B.; Quintana-Murci, L. The heritage of pathogen pressures and ancient demography in the human innate-immunity CD209/CD209L region. Am. J. Hum. Genet. 2005, 77, 869-886.
208. Davis, C.W.; Nguyen, H.Y.; Hanna, S.L.; Sanchez, M.D.; Doms, R.W.; Pierson, T.C. West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J. Virol 2006, 80, 1290-1301.
209. Mummidi, S.; Catano, G.; Lam, L.; Hoefle, A.; Telles, V.; Begum, K.; Jimenez, F.; Ahuja, S.S.; Ahuja, S.K. Extensive repertoire of membrane-bound and soluble dendritic cell-specific ICAM-3-grabbing nonintegrin 1 (DC-SIGN1) and DC-SIGN2 isoforms. Inter-individual variation in expression of DC-SIGN transcripts. J. Biol. Chem. 2001, 276, 33196-33212.
210. Plazolles, N.; Humbert, J.M.; Vachot, L.; Verrier, B.; Hocke, C.; Halary, F. Pivotal advance: The promotion of soluble DC-SIGN release by inflammatory signals and its enhancement of cytomegalovirus-mediated cis-infection of myeloid dendritic cells. J. Leukoc. Biol. 2011, 89, 329-342.
211. Serrano-Gómez, D.; Sierra-Filardi, E.; Martinez-Nunez, R.T.; Caparros, E.; Delgado, R.; Munoz-Fernandez, M.A.; Abad, M.A.; Jimenez-Barbero, J.; Leal, M.; Corbi, A.L. Structural requirements for multimerization of the pathogen receptor dendritic cell-specific ICAM3-grabbing non-integrin (CD209) on the cell surface. J. Biol. Chem. 2008, 283, 3889-3903.
212. Alagarasu, K.; Selvaraj, P.; Swaminathan, S.; Raghavan, S.; Narendran, G.; Narayanan, P.R. CCR2, MCP-1, SDF-1a & DC-SIGN gene polymorphisms in HIV-1 infected patients with & without tuberculosis. Indian J. Med. Res. 2009, 130, 444-450.
213. Zhang, J.; Zhang, X.; Fu, J.; Bi, Z.; Arheart, K.L.; Barreiro, L.B.; Quintana-Murci, L.; Pahwa, S.; Liu, H. Protective role of DC-SIGN (CD209) neck-region alleles with <5 repeat units in HIV-1 transmission. J. Infect. Dis. 2008, 198, 68-71.
214. Liu, H.; Hwangbo, Y.; Holte, S.; Lee, J.; Wang, C.; Kaupp, N.; Zhu, H.; Celum, C.; Corey, L.; McElrath, M.J.; et al. Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1. J. Infect. Dis. 2004, 190, 1055-1058.
215. Nguyen, D.G.; Hildreth, J.E. Involvement of macrophage mannose receptor in the binding and transmission of HIV by macrophages. Eur. J. Immunol. 2003, 33, 483-493.
216. Trujillo, J.R.; Rogers, R.; Molina, R.M.; Dangond, F.; McLane, M.F.; Essex, M.; Brain, J.D. Noninfectious entry of HIV-1 into peripheral and brain macrophages mediated by the mannose receptor. Proc. Natl. Acad. Sci. USA 2007, 104, 5097-5102.
217. Hartshorn, K.L.; Sastry, K.N.; Chang, D.; White, M.R.; Crouch, E.C. Enhanced anti-influenza activity of a surfactant protein D and serum conglutinin fusion protein. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000, 278, L90-L98.
218. Yang, L.; Hu, S.; Chroneos, Z. Targeting of the surfactant protein A receptor SP-R210L variant by influenza A virus in macrophages. (INM8P.440). J. Immunol. 2014, 192, 124-126.
219. Pandit, H.; Gopal, S.; Sonawani, A.; Yadav, A.K.; Qaseem, A.S.; Warke, H.; Patil, A.; Gajbhiye, R.; Kulkarni, V.; Al-Mozaini, M.A.; et al. Surfactant protein D inhibits HIV-1 infection of target cells via interference with gp120-CD4 interaction and modulates pro-inflammatory cytokine production. PLoS One 2014, 9, e102395.
220. Madsen, J.; Gaiha, G.D.; Palaniyar, N.; Dong, T.; Mitchell, D.A.; Clark, H.W. Surfactant Protein D modulates HIV infection of both T-cells and dendritic cells. PLoS One 2013, 8, e59047.
221. Gaiha, G.D.; Dong, T.; Palaniyar, N.; Mitchell, D.A.; Reid, K.B.; Clark, H.W. Surfactant protein A binds to HIV and inhibits direct infection of CD4+ cells, but enhances dendritic cell-mediated viral transfer. J. Immunol. 2008, 181, 601-609.
222. Sano, H.; Nagai, K.; Tsutsumi, H.; Kuroki, Y. Lactoferrin and surfactant protein A exhibit distinct binding specificity to F protein and differently modulate respiratory syncytial virus infection. Eur. J. Immunol. 2003, 33, 2894-2902.
223. St-Pierre, C.; Manya, H.; Ouellet, M.; Clark, G.F.; Endo, T.; Tremblay, M.J.; Sato, S. Host-soluble galectin-1 promotes HIV-1 replication through a direct interaction with glycans of viral gp120 and host CD4. J. Virol. 2011, 85, 11742-11751.
224. Bi, S.; Hong, P.W.; Lee, B.; Baum, L.G. Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry. Proc. Natl. Acad. Sci. USA 2011, 108, 10650-10655.
225. Wang, S.F.; Tsao, C.H.; Lin, Y.T.; Hsu, D.K.; Chiang, M.L.; Lo, C.H.; Chien, F.C.; Chen, P.; Arthur Chen, Y.M.; Chen, H.Y.; et al. Galectin-3 promotes HIV-1 budding via association with Alix and Gag p6. Glycobiology 2014, 24, 1022-1035.
226. De Witte, L.; Nabatov, A.; Pion, M.; Fluitsma, D.; de Jong, M.A.; de Gruijl, T.; Piguet, V.; van Kooyk, Y.; Geijtenbeek, T.B. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat. Med. 2007, 13, 367-371.
227. Van der Vlist, M.; de Witte, L.; de Vries, R.D.; Litjens, M.; de Jong, M.A.; Fluitsma, D.; de Swart, R.L.; Geijtenbeek, T.B. Human Langerhans cells capture measles virus through Langerin and present viral antigens to CD4(+) T cells but are incapable of cross-presentation. Eur. J. Immunol. 2011, 41, 2619-2631.
228. Valdimarsson, H. Infusion of plasma-derived mannan-binding lectin (MBL) into MBL-deficient humans. Biochem. Soc. Trans. 2003, 31, 768-769.
229. Laursen, I. Mannan-binding lectin (MBL) production from human plasma. Biochem. Soc. Trans. 2003, 31, 758-762.
230. Jensenius, J.C.; Jensen, P.H.; McGuire, K.; Larsen, J.L.; Thiel, S. Recombinant mannan-binding lectin (MBL) for therapy. Biochem. Soc. Trans. 2003, 31, 763-767.
231. Petersen, K.A.; Matthiesen, F.; Agger, T.; Kongerslev, L.; Thiel, S.; Cornelissen, K.; Axelsen, M. Phase I safety, tolerability, and pharmacokinetic study of recombinant human mannan-binding lectin. J. Clin. Immunol. 2006, 26, 465-475.
232. Michelow, I.C.; Dong, M.; Mungall, B.A.; Yantosca, L.M.; Lear, C.; Ji, X.; Karpel, M.; Rootes, C.L.; Brudner, M.; Houen, G.; et al. A novel L-ficolin/mannose-binding lectin chimeric molecule with enhanced activity against Ebola virus. J. Biol. Chem. 2010, 285, 24729-24739.
233. White, M.R.; Crouch, E.; Chang, D.; Sastry, K.; Guo, N.; Engelich, G.; Takahashi, K.; Ezekowitz, R.A.; Hartshorn, K.L. Enhanced antiviral and opsonic activity of a human mannose-binding lectin and surfactant protein D chimera. J. Immunol. 2000, 165, 2108-2115.
234. Takahashi, K.; Moyo, P.; Chigweshe, L.; Chang, W.C.; White, M.R.; Hartshorn, K.L. Efficacy of recombinant chimeric lectins, consisting of mannose binding lectin and L-ficolin, against influenza A viral infection in mouse model study. Virus Res. 2013, 178, 495-501.
235. Chang, W.C.; Hartshorn, K.L.; White, M.R.; Moyo, P.; Michelow, I.C.; Koziel, H.; Kinane, B.T.; Schmidt, E.V.; Fujita, T.; Takahashi, K. Recombinant chimeric lectins consisting of mannose-binding lectin and L-ficolin are potent inhibitors of influenza A virus compared with mannose-binding lectin. Biochem. Pharmacol. 2011, 81, 388-395.
236. Crouch, E.; Nikolaidis, N.; McCormack, F.X.; McDonald, B.; Allen, K.; Rynkiewicz, M.J.; Cafarella, T.M.; White, M.; Lewnard, K.; Leymarie, N.; et al. Mutagenesis of surfactant protein D informed by evolution and x-ray crystallography enhances defenses against influenza A virus in vivo. J. Biol. Chem. 2011, 286, 40681-40692.
237. Hillaire, M.L.; van Eijk, M.; Vogelzang-van Trierum, S.E.; Fouchier, R.A.; Osterhaus, A.D.; Haagsman, H.P.; Rimmelzwaan, G.F. Recombinant porcine surfactant protein D inhibits influenza A virus replication ex vivo. Virus Res. 2014, 181, 22-26.
238. Tarr, A.W.; Urbanowicz, R.A.; Ball, J.K. The role of humoral innate immunity in hepatitis C virus infection. Viruses 2012, 4, 1-27.
239. Marzi, A.; Mitchell, D.A.; Chaipan, C.; Fisch, T.; Doms, R.W.; Carrington, M.; Desrosiers, R.C.; Pohlmann, S. Modulation of HIV and SIV neutralization sensitivity by DC-SIGN and mannose-binding lectin. Virology 2007, 368, 322-330.
240. Boross, P.; Leusen, J.H. Boosting antibody therapy with complement. Blood 2012, 119, 5945-5947.
241. Alexandre, K.B.; Gray, E.S.; Mufhandu, H.; McMahon, J.B.; Chakauya, E.; O'Keefe, B.R.; Chikwamba, R.; Morris, L. The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells. Virology 2012, 423, 175-186.
242. Balzarini, J.; Francois, K.O.; van Laethem, K.; Hoorelbeke, B.; Renders, M.; Auwerx, J.; Liekens, S.; Oki, T.; Igarashi, Y.; Schols, D. Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use. Antimicrob. Agents Chemother. 2010, 54, 1425-1435.
243. Buffa, V.; Stieh, D.; Mamhood, N.; Hu, Q.; Fletcher, P.; Shattock, R.J. Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. J. Gen. Virol. 2009, 90, 234-243.
244. Tsai, C.C.; Emau, P.; Jiang, Y.; Agy, M.B.; Shattock, R.J.; Schmidt, A.; Morton, W.R.; Gustafson, K.R.; Boyd, M.R. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res. Hum. Retrovir. 2004, 20, 11-18.
245. Whitley, M.J.; Furey, W.; Kollipara, S.; Gronenborn, A.M. Burkholderia oklahomensis agglutinin is a canonical two-domain OAA-family lectin: Structures, carbohydrate binding and anti-HIV activity. FEBS J. 2013, 280, 2056-2067.
246. Ferir, G.; Huskens, D.; Noppen, S.; Koharudin, L.M.; Gronenborn, A.M.; Schols, D. Broad anti-HIV activity of the Oscillatoria agardhii agglutinin homologue lectin family. J. Antimicrob. Chemother. 2014, 69, 2746-2758.
247. Liu, X.; Lagenaur, L.A.; Simpson, D.A.; Essenmacher, K.P.; Frazier-Parker, C.L.; Liu, Y.; Tsai, D.; Rao, S.S.; Hamer, D.H.; Parks, T.P.; et al. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob. Agents Chemother. 2006, 50, 3250-3259.
248. Koharudin, L.M.; Furey, W.; Gronenborn, A.M. Novel fold and carbohydrate specificity of the potent anti-HIV cyanobacterial lectin from Oscillatoria agardhii. J. Biol. Chem. 2011, 286, 1588-1597.
249. Meuleman, P.; Albecka, A.; Belouzard, S.; Vercauteren, K.; Verhoye, L.; Wychowski, C.; Leroux-Roels, G.; Palmer, K.E.; Dubuisson, J. Griffithsin has antiviral activity against hepatitis C virus. Antimicrob. Agents Chemother. 2011, 55, 5159-5167.
250. O'Keefe, B.R.; Giomarelli, B.; Barnard, D.L.; Shenoy, S.R.; Chan, P.K.; McMahon, J.B.; Palmer, K.E.; Barnett, B.W.; Meyerholz, D.K.; Wohlford-Lenane, C.L.; et al. Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J. Virol. 2010, 84, 2511-2521.
251. Ishag, H.Z.; Li, C.; Huang, L.; Sun, M.X.; Wang, F.; Ni, B.; Malik, T.; Chen, P.Y.; Mao, X. Griffithsin inhibits Japanese encephalitis virus infection in vitro and in vivo. Arch. Virol. 2013, 158, 349-358.
252. Takebe, Y.; Saucedo, C.J.; Lund, G.; Uenishi, R.; Hase, S.; Tsuchiura, T.; Kneteman, N.; Ramessar, K.; Tyrrell, D.L.; Shirakura, M.; et al. Antiviral lectins from red and blue-green algae show potent in vitro and in vivo activity against hepatitis C virus. PLoS One 2013, 8, e64449.
253. Helle, F.; Wychowski, C.; Vu-Dac, N.; Gustafson, K.R.; Voisset, C.; Dubuisson, J. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J. Biol. Chem. 2006, 281, 25177-25183.
254. Dey, B.; Lerner, D.L.; Lusso, P.; Boyd, M.R.; Elder, J.H.; Berger, E.A. Multiple antiviral activities of cyanovirin-N: Blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J. Virol. 2000, 74, 4562-4569.
255. Smee, D.F.; Bailey, K.W.; Wong, M.H.; O'Keefe, B.R.; Gustafson, K.R.; Mishin, V.P.; Gubareva, L.V. Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N. Antivir. Res. 2008, 80, 266-271.
256. Bertaux, C.; Daelemans, D.; Meertens, L.; Cormier, E.G.; Reinus, J.F.; Peumans, W.J.; van Damme, E.J.; Igarashi, Y.; Oki, T.; Schols, D.; et al. Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. Virology 2007, 366, 40-50.
257. Boyd, M.R.; Gustafson, K.R.; McMahon, J.B.; Shoemaker, R.H.; O'Keefe, B.R.; Mori, T.; Gulakowski, R.J.; Wu, L.; Rivera, M.I.; Laurencot, C.M.; et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development. Antimicrob. Agents Chemother. 1997, 41, 1521-1530.
258. Chen, J.; Huang, D.; Chen, W.; Guo, C.; Wei, B.; Wu, C.; Peng, Z.; Fan, J.; Hou, Z.; Fang, Y.; et al. Linker-extended native cyanovirin-N facilitates PEGylation and potently inhibits HIV-1 by targeting the glycan ligand. PLoS One 2014, 9, e86455.
259. Barton, C.; Kouokam, J.C.; Lasnik, A.B.; Foreman, O.; Cambon, A.; Brock, G.; Montefiori, D.C.; Vojdani, F.; McCormick, A.A.; O'Keefe, B.R.; et al. Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. Antimicrob. Agents Chemother. 2014, 58, 120-127.
260. Xiong, S.; Fan, J.; Kitazato, K. The antiviral protein cyanovirin-N: The current state of its production and applications. Appl. Microbiol. Biotechnol. 2010, 86, 805-812.